Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: Preclinical and preliminary clinical data

Journal of Medical Microbiology

Volumn 54, Issue 2, 2005, Pages 197-205

  Van Dissel, Jaap T ^a   De Groot, Manda ^b   Hensgens, Charles M H ^b   Numan, Sandra ^a   Kuijper, Ed J ^a   Veldkamp, Peter ^a,c   Van't Wout, Jan ^a,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MucoVax BV   (Netherlands)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; MILK PROTEIN; SLGA ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN; WHEY PROTEIN; BACTERIUM ANTIBODY;

ADOLESCENT; ADULT; AGED; BACTERIAL INFECTION; BACTERIUM CULTURE; CELL ASSAY; CHILD; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RELAPSE; WHEY; ANIMAL; ARTICLE; CATTLE; COHORT ANALYSIS; HAMSTER; IMMUNOLOGY; PILOT STUDY; PROSPECTIVE STUDY;

ANIMALS; ANTIBODIES, BACTERIAL; CATTLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; CRICETINAE; DIARRHEA; HUMANS; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 15544372508     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.45773-0     Document Type: Conference Paper

References (28)

1. Aas, J., Gessert, C. E. & Bakken, J. S. (2003). Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36, 580-585.
2. Aspinall, S. T. & Hutchinson, D. N. (1992). New selective medium for isolating Clostridium difficile from feces. J Clin Pathol 45, 812-814.
3. Barbut, F. & Petit, J.-C. (2001). Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 8, 405-411.
4. Bennett, B. G., Gorbach, S. L., Goldin, B. R., Chang, T. W., Laughon, B. E., Greenough, W. B., III & Bartlett, J. G. (1996). Treatment of relapsing Clostridium difficile diarrhoea with Lactobacillus GG. Nutrition Today 31 (Suppl), 35-38.
5. Bignardi, G. E. (1998). Risk factors for Clostridium difficile infection. J Hospital Infect 40, 1-15.
6. Burbige, E. J. & Milligan, F. D. (1975). Pseudomembranous colitis. Association with antibiotics and therapy with cholestyramine. JAMA 231, 1157-1158.
7. Chang, T. W., Bartlett, J. G., Gorbach, S. L. & Onderdonk, A. B. (1978). Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun 20, 526-529.
8. Fagarasan, S. & Honjo, T. (2003). Intestinal IgA synthesis: regulation of front-line body defense. Nature Rev Immunol 3, 63-72.
9. Fedorko, D. P. & Williams, E. C. (1997). Use of cycloserine- cefoxiton-fructose agar and L-prolin-aminopeptidase PRO discs in the rapid identification of Clostridium difficile. J Clin Microbiol 35, 1258-1259.
10. Kelly, C. P., Pothoulakis, C. & Lamont, J. T. (1994). Clostridium difficile colitis. N Engl J Med 330, 257-262.
11. Kelly, C. P., Pothoulakis, C., Vavva, F., Castagliuolo, I., Bostwick, E. F., O'Keane, J. C., Keates, S. & LaMont, J. T. (1996). Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 40, 373-379.
12. Kelly, C. P., Chetham, S., Keates, S., Bostwick, E. F., Roush, A. M., Castagliuolo, I., LaMont, J. T. & Pothoulakis, C. (1997). Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 41, 236-241.
13. Kurtz, C. B., Cannon, E. P., Brezzani, A. & 12 other authors (2001). GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 45, 2340-2347.
14. Leung, D. Y., Kelly, C. P., Boguniewicz, M., Pothoulakis, C., LaMont, J. T. & Flores, A. (1991). Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118, 633-637.
15. Lyerly, D. M., Bostwick, E. F., Binion, S. B. & Wilkins, T. D. (1991). Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 59, 2215-2218.
16. McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y. & Stamm, W. E. (1989). Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320, 204-210.
17. McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Fekety, R., Elmer, G. W., Moyer, K. A., Melcher, S. A., Bowen, K. E., Cox, J. L. & Noorani, Z. (1994). A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271, 1913-1918.
18. McNulty, C., Logan, M., Donald, I. P., Ennis, D., Taylor, D., Baldwin, R. N., Bannerjee, M. & Cartwright, K. A. (1997). Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 40, 707-711.
19. Minekus, M. & Havenaar, R. (1996). In Vitro Model of an In Vivo Digestive Tract. United States Patent, no. 5,525,305.
20. Spencer, R. C. (1998). Clinical impact and associated costs of Clostridium difficile-associated disease. J Antimicrob Chemother 41, 5-12.
21. Stoddart, B. & Wilcox, M. H. (2001). Clostridium difficile. Curr Opin Infect Dis 15, 513-518.
22. Sullivan, N. M., Pellett, S. & Wilkins, T. D. (1982). Purification and characterization of Toxin A and B of Clostridium difficile. Infect Immun 35, 1032-1040.
23. Surawicz, C. M., Elmer, G. W., Speelman, P., McFarland, L. V., Chinn, J. & van Belle, G. (1989). Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: a prospective study. Gastroenterohgy 96, 981-988.
24. Taylor, N. S. & Bartlett, J. G. (1980). Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141, 92-97.
25. Tedesco, F. J. (1982). Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 77, 220-221.
26. Thomas, M. R., Litin, S. C., Osmon, D. R., Corr, A. P., Weaver, A. L. & Lohse, C. M. (2001). Lack of effect of Lactobacillus GG on antibiotic-associated diarrhoea: a randomized, placebo-controlled trial. Mayo Clin Proc 76, 883-889.
27. Warny, M., Fatimi, A., Bostwick, E. F., Laine, D. C., Lebel, F., LaMont, J. T., Pothoulakis, C. & Kelly, C. P. (1999). Bovine immunoglobulin concentrate-Clostridium difficile retains C. difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 44, 212-217.
28. Wilcox, M. H., Cunniffe, J. G., Trundle, C. & Redpath, C. (1996). Financial burden of hospital acquired Clostridium difficile infection. J Hosp Infect 34, 23-30.